Australia Medical Cannabis: What the UK Can Learn

Australia’s Therapeutic Goods Administration Framework

• The TGA regulates medical cannabis in Australia under the Therapeutic Goods Act 1989
• Australia uses a Special Access Scheme pathway for unapproved cannabis medicines
• Authorised Prescriber status allows clinicians to prescribe to multiple patients without individual applications
• Australia has seen rapid growth in approvals, exceeding 350,000 approvals by recent counts

Australia’s medical cannabis programme has been one of the fastest-growing globally, driven by the TGA’s development of pragmatic regulatory pathways that have reduced administrative barriers for prescribers. The Special Access Scheme and Authorised Prescriber pathways provide a degree of flexibility that has contributed significantly to market growth. The UK’s specialist-only model and the Australian TGA approach represent different regulatory philosophies with different access outcomes.

GP Prescribing: Australia’s Key Differentiator

• Australian GPs can prescribe cannabis medicines through the Authorised Prescriber pathway
• GP prescribing has dramatically expanded the prescribing base beyond specialist clinics
• Patient access barriers have been significantly reduced by primary care availability
• GP prescribing requires appropriate training and clinical governance safeguards

The most significant structural difference between Australia and the UK in medical cannabis access is the role of general practitioners. In Australia, GPs who have obtained Authorised Prescriber status can prescribe cannabis medicines to appropriate patients without specialist involvement in every case. This structural shift has been a major driver of volume growth and patient access. It is a model that UK advocates regularly cite when calling for reform of the UK’s specialist-only restriction.

Product Approval and Quality Standards

• Australian medical cannabis products must be either TGA-registered or approved under access schemes
• Good Manufacturing Practice certification is required for all approved products
• The TGA conducts its own manufacturing inspections for Australian domestic production
• International suppliers must demonstrate compliance with TGA-recognised GMP standards

Australia’s product quality standards are comparable to those applied in the UK, with GMP certification being a fundamental requirement. The difference lies in the product approval pathway: the UK’s unlicensed special route and Australia’s special access scheme both permit access to unapproved products, but with slightly different documentation and justification requirements. For importers active in both markets, the core quality requirements are broadly aligned.

Australian Insights for UK Clinical Practice

• Real-world data from Australian programmes covers a broader patient population than UK data
• Australian GPs have developed tools and guidelines for integrating cannabis into primary care
• Adverse event profiles from Australian data are directly relevant to UK clinical decision-making
• Australian patient outcomes data across a range of conditions strengthens the global evidence base

Australia’s rapid scaling of medical cannabis across primary and specialist care has generated a rich and growing body of clinical insights. For UK clinicians working within the specialist prescribing model, Australian real-world data provides valuable benchmarks for patient selection, dosing approaches, and adverse event management. Engagement with Australian clinical literature is increasingly part of best practice for UK medical cannabis prescribers.